Use of prasugrel vs clopidogrel and outcomes in patients with and without diabetes mellitus presenting with acute coronary syndrome undergoing percutaneous coronary intervention
Author:
Funder
Eli Lilly and Company
Daiichi Sankyo Company
AstraZeneca
The Medicines Co.
OrbusNeich
Bayer
CSL Behring
Publisher
Elsevier BV
Subject
Cardiology and Cardiovascular Medicine
Reference17 articles.
1. Influence of diabetes mellitus on clinical outcomes following primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction;Jensen;Am. J. Cardiol.,2012
2. Diabetes and mortality following acute coronary syndromes;Donahoe;JAMA,2007
3. Impact of diabetes mellitus on ischemic events in men and women after percutaneous coronary intervention;Farhan;Am. J. Cardiol.,2017
4. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial;James;Eur. Heart J.,2010
5. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Research Progress on Related Genes of Clopidogrel Resistance;Advances in Clinical Medicine;2023
2. COMPARISON OF CLINICAL AND ANGIOGRAPHIC CHARACTERISTICS OF DIABETIC AND NON-DIABETIC PATIENTS WITH ACUTE MYOCARDIAL INFARCTION;Pakistan Heart Journal;2022-12-31
3. The DNAm levels of CREB5 (cg11301281) were associated with clopidogrel resistance;Journal of Clinical Laboratory Analysis;2022-09-10
4. Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis;International Journal of Molecular Sciences;2022-02-20
5. Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors;Diabetes Research and Clinical Practice;2022-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3